Trade Names:Lovenox- Injection 30 mg per 0.3 mL- Injection 40 mg per 0.4 mL- Injection 60 mg per 0.6 mL- Injection 80 mg per 0.8 mL- Injection 100 mg/mL- Injection 120 mg per 0.8 mL- Injection 150 mg/mL- Injection 300 mg per 3 mLLovenox HP (Canada)
Causes higher anti-factor Xa to antithrombin activities (anti-factor IIa) ratio than heparin, which may prevent thrombosis.
Bioavailability is 92%.
Vd is approximately 6 L (for anti-factor Xa activity).
Metabolized in the liver by desulfation and/or depolymerization to low molecular weight species.
Cl is approximately 15 mL/min. The t ½ is 4.5 h (based on anti-factor Xa activity).
3 to 5 h.
Cl is approximately 30% lower in those with severe renal function impairment (CrCl less than 30 mL/min).Gender
Apparent clearance and maximum observed activity derived from anti-Factor Xa values following subcutaneous dosing were slightly higher in males than in females.Weight
Mean AUC of anti-Factor Xa activity is marginally higher at steady state in obese healthy patients.
Prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery or abdominal surgery; in conjunction with warfarin for inpatient treatment of acute DVT with or without PE, or outpatient treatment of acute DVT without PE; prevention of ischemic complications of unstable and non–Q-wave MI when coadministered with aspirin. In medical patients who are at risk for thromboembolic complications because of severely restricted mobility during acute illness.
Treatment of acute ST-segment elevation MI (STEMI).
Hypersensitivity to enoxaparin, heparin, benzyl alcohol, or pork products; active major bleeding; thrombocytopenia associated with positive in vitro test for antiplatelet antibody in presence of enoxaparin.
Subcutaneous 30 mg twice daily, with initial dose given within 12 to 24 h postoperatively, provided hemostasis has been established. Average duration of administration is 7 to 10 days, up to 14 days. For hip replacement surgery, 40 mg every day, given initially 9 to 15 h prior to surgery may be considered; continue prophylaxis for 3 wk.Abdominal SurgeryAdults
Subcutaneous 40 mg/day with the initial dose given 2 h prior to surgery. Usual duration of administration is 7 to 10 days, up to 12 days.Acute IllnessAdults
Subcutaneous 40 mg every day for 6 to 11 days, up to 14 days, in patients at risk for thromboembolic complications caused by severely restricted mobility during acute illness.DVT/PE TreatmentAdults, Outpatient
Subcutaneous 1 mg/kg every 12 h.Adults, Inpatient
Subcutaneous 1 mg/kg every 12 h or 1.5 mg/kg every day (same time each day).Adults, Outpatient and Inpatient
Initiate warfarin therapy when appropriate (usually within 72 h of enoxaparin). Continue enoxaparin for a minimum of 5 days and until a therapeutic anticoagulant effect has been achieved. The average duration is 7 days; up to 17 days has been well tolerated.Unstable Angina/Non–Q-Wave MIAdults
Subcutaneous 1 mg/kg every 12 h in conjunction with oral aspirin therapy (100 to 325 mg every day); usual duration of treatment is 2 to 8 days, up to 12.5 days.Acute STEMIAdults
IV/Subcutaneous Single IV bolus of 30 mg plus a 1 mg/kg subcutaneous dose followed by 1 mg/kg every 12 hr (max, 100 mg for first 2 doses only, followed by 1 mg/kg dosing for the remaining doses).Renal Function ImpairmentAdults
Subcutaneous No dosage adjustment is recommended for mild (CrCl 50 to 80 mL/min) or moderate (CrCl 30 to 50 mL/min) impairment. Severe renal function impairment (Crcl less than 30 mL/min):Prophylaxis in abdominal surgery or hip or knee replacement surgery; prophylaxis in medical patients during acute illness
30 mg subcutaneous once daily.Inpatient DVT with or without PE in conjunction with warfarin; outpatient treatment of DVT without PE in conjunction with warfarin; prophylaxis of ischemic complications of unstable angina and non–Q-wave MI in conjunction with aspirin; acute STEMI in patients 75 yr of age or older (no initial bolus)
1 mg/kg subcutaneous once daily.Acute STEMI in patients younger than 75 yr of age
30 mg IV bolus plus 1 mg/kg subcutaneously followed by 1 mg/kg subcutaneously once daily.ElderlyAdults
For treatment of acute STEMI in elderly patients at least 75 years of age, do not use an initial IV bolus. Initiate dosing with 0.75 mg/kg subcutaneous every 12 h (max 75 mg for the first 2 doses only, followed by 0.75 mg/kg dosing for the remaining doses).
Store at room temperature (59° to 86°F). Do not freeze.
Use enoxaparin with caution because of increased risk of hemorrhagic reactions.
Do not mix enoxaparin with other injections or infusions.
Drug causes asymptomatic elevations in AST and ALT.
Cutaneous vasculitis, purpura, vesiculobullous rash (postmarketing).
Nausea (3%); diarrhea (2%).
Anemia (16%); hemorrhage (13%); major bleeding (4%); thrombocytopenia (3%); thrombocytopenia with thrombosis, thrombocytosis (postmarketing).
Increased AST and ALT greater than 3 times ULN (6%); hyperlipidemia, hypertriglyceridemia (postmarketing).
Injection-site hemorrhage (5%); ecchymosis (3%); injection-site pain (2%); erythema, hematoma, mild local irritation, pain, injection-site reactions, including anaphylactoid reactions, pruritus, urticaria (postmarketing).
Fever (8%); peripheral edema (6%); dyspnea epidural (3%); spinal hematoma (postmarketing).
Risk of spinal/epidural hematoma increased in patients receiving neuraxial anesthesia or spinal puncture and who are anticoagulated with LMWH or heparinoids. Other risk factors include indwelling epidural catheters, repeated or traumatic epidural or spinal puncture, or other drugs affecting hemostasis (eg, NSAIDs, platelet inhibitors, anticoagulants). Risk of long-term or permanent paralysis. Monitor frequently for signs/symptoms of neurological impairment.
Periodic CBCs, including platelet count, and stool occult blood tests are recommended
Category B .
Safety and efficacy not established.
Delayed elimination of drug possible. Use with caution.
Delayed elimination of drug may occur. Use with caution.
Dosage adjustments are recommended in severe hepatic function impairment.
Use drug with caution in patients with diabetic retinopathy, bleeding diathesis, uncontrolled arterial hypertension, or history of recent GI ulceration and hemorrhage.
Multiple-dose vials contain benzyl alcohol as a preservative; has been associated with a fatal “gasping syndrome” in premature neonates.
Use drug with extreme caution in patients with conditions associated with increased risk of hemorrhage.
Cannot be used interchangeably (unit for unit) with heparin or other LMWHs.
To minimize the risk of bleeding, adhere precisely to the recommended dosing intervals.
Use is not recommended for thromboprophylaxis in patients with prosthetic heart valves.
There have been reports of congenital anomalies in infants born to women who received enoxaparin during pregnancy, including cerebral anomalies, limb anomalies, hypospadias, peripheral vascular malformation, fibrotic dysplasia, and cardiac defects. A cause-and-effect relationship has not been established.
Use with extreme caution in patients who have a history of heparin-induced thrombocytopenia. Closely monitor any degree of thrombocytopenia.
Copyright © 2009 Wolters Kluwer Health.